Background: The randomized, phase 3 CheckMate 025 study of nivolumab (n = 410) versus everolimus (n = 411) in previously treated adults (75% male; 88% white) with advanced renal cell carcinoma (aRCC) demonstrated significantly improved overall survival (OS) and objective response rate (ORR). Objective: To investigate which baseline factors were associated with OS and ORR benefit with nivolumab versus everolimus. Design, setting, and participants: Subgroup OS analyses were performed using Kaplan-Meier methodology. Hazard ratios were estimated using the Cox proportional hazards model. Intervention: Nivolumab 3 mg/kg every 2 wk or everolimus 10 mg once daily. Results and limitations: The minimum follow-up was 14 mo. Baseline subgroup distributions were balanced between nivolumab and everolimus arms. Nivolumab demonstrated an OS improvement versus everolimus across subgroups, including Memorial Sloan Kettering Cancer Center (MSKCC) and International Metastatic Renal Cell Carcinoma Database Consortium risk groups; age <65 and 65 yr; one and two or more sites of metastases; bone, liver, and lung metastases; number of prior therapies; duration of Please visit www.eu-acme.org/ europeanurology to read and answer questions on-line.
1.

Introduction
As the treatment paradigm for advanced renal cell carcinoma (aRCC) shifts in response to the development and approval of new therapies, a deeper understanding of patient baseline factors and/or disease characteristics affecting clinical outcomes is necessary and may help in guiding treatment decisions. Prognostic models for RCC have been developed that incorporate factors such as performance status, time from diagnosis to treatment, hemoglobin, calcium and lactate dehydrogenase concentrations, and neutrophil and platelet counts [1, 2] . These models are limited because they were developed before the advent of modern immunotherapies and they do not include other factors that have also been shown to be associated with prognosis, such as the number and duration of prior therapies, sites of metastases, and age [3] [4] [5] [6] . Further investigation of prognostic factors is needed for the development of risk models that more accurately reflect the current treatment landscape.
The phase 3 CheckMate 025 study in previously treated patients with aRCC demonstrated superior overall survival (OS) with nivolumab compared with everolimus [7] . Median OS was 25.0 mo (95% confidence interval [CI] 21.8-not reached [NR]) for nivolumab versus 19.6 mo (95% CI 17.6-23.1) for everolimus. The investigatorassessed objective response rate (ORR) was 25% versus 5% (p < 0.001) [7] , while the confirmed ORR was 22% versus 4% [8] . Treatment with nivolumab also provided an OS benefit versus everolimus across prespecified subgroups of patients, including those with different Memorial Sloan Kettering Cancer Center (MSKCC) risk, number of prior antiangiogenic therapies, geographical region, age, and sex. [7] .
The objectives of this analysis were to investigate further whether the OS and ORR benefits observed with nivolumab versus everolimus in the overall population were also observed in patients with poor prognostic baseline disease, and if demographic and pretreatment characteristics, including prior therapy, with an impact on outcomes with nivolumab can be identified.
2.
Patients and methods
Patients
Adults with histological confirmation of aRCC with a clear-cell component were eligible. Additional eligibility criteria were reported previously [7] . 
Study design and treatments
This was a phase 3, randomized, open-label study of nivolumab versus everolimus. The detailed study design was described previously [7] . Patients were randomized 1:1 to receive nivolumab 3 mg/kg intravenously for 60 min every 2 wk or an everolimus 10-mg tablet orally once daily. 
Endpoints and assessments
Study oversight
This study was approved by the institutional review board or independent ethics committee at each center and conducted in accordance with Good Clinical Practice guidelines defined by the International Conference on prior therapy; and prior sunitinib, pazopanib, or interleukin-2 therapy. The benefit with nivolumab versus everolimus was noteworthy for patients with poor MSKCC risk (hazard ratio 0.48, 95% confidence interval 0.32-0.70). The mortality rate at 12 mo for all subgroups was lower with nivolumab compared with everolimus. ORR also favored nivolumab. The incidence of grade 3 or 4 treatment-related adverse events across subgroups was lower with nivolumab. Limitations include the post hoc analysis and differing sample sizes between groups. Conclusion: The trend for OS and ORR benefit with nivolumab for multiple subgroups, without notable safety concerns, may help to guide treatment decisions, and further supports nivolumab as the standard of care in previously treated patients with aRCC. Patient summary: We investigated the impact of demographic and pretreatment features on survival benefit and tumor response with nivolumab versus everolimus in advanced renal cell carcinoma (aRCC). Survival benefit and response were observed for multiple subgroups, supporting the use of nivolumab as a new standard of care across a broad range of patients with previously treated aRCC.
The trial is registered on ClinicalTrials.gov as NCT01668784.
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Harmonisation. All patients provided written informed consent to participate according to the principles of the Declaration of Helsinki.
Statistical analyses
Descriptive statistics for categorical variables are reported as frequencies and percentages. OS was estimated using the Kaplan-Meier productlimit methods [10] ; median OS and 95% CI were reported using Brookmeyer and Crowley methods [11] ; 95% CIs were constructed via log-log transformation. Hazard ratios for nivolumab versus everolimus were estimated using the Cox proportional hazards model with treatment group as a single covariate [12] . Unstratified hazard ratios and corresponding 95% CIs were used to generate a forest plot of OS comprising each subgroup. A forest plot of the unweighted differences in ORR between nivolumab and everolimus and corresponding 95% CI using the Newcombe approach was produced across subgroups [13] . To assess whether the relationship between OS and treatment differed by various patient characteristics of interest, we separately tested the interaction between treatment and each baseline characteristic using a Cox proportional hazards model. Similarly, for ORR and treatment-related adverse event (TRAE) rates, the interaction between treatment and each baseline characteristic was tested using a logistic regression model.
Continuous variables were only used for the interaction test for age (in years) and duration of prior therapy (in months); for all other subgroups, categorical variables were used. The analyses were conducted using SAS version 9 software (SAS Institute Inc., Cary, NC, USA).
Results
Patients
The analyses included 410 and 411 patients randomized to nivolumab and everolimus, respectively, between October 2012 and March 2014 ( Supplementary Fig. 1 ). The distribution of patients in each subgroup was balanced between nivolumab and everolimus ( Table 1 ). The minimum follow-up was 14 mo. The median follow-up among the 227 nivolumab-randomized and 196 everolimus-randomized patients who had not died at data cutoff was 22 mo (interquartile range [IQR] 20-25) and 22 mo (IQR 20-25). At data cutoff (June 2015), 67 of 406 nivolumabtreated and 28 of 397 everolimus-treated patients continued to receive treatment. The number who continued to receive treatment in each subgroup is shown in Supplementary Fig. 1 . Consistent with the overall population, the primary reason for discontinuation in all subgroups was disease progression. The baseline disease characteristics of patients by subgroups were generally similar between nivolumab and everolimus (Supplementary Table 1 ).
OS by prognostic risk group
In an assessment of OS by favorable, intermediate, and poor MSKCC risk groups, median OS was longer in both arms in patients with better MSKCC scores ( Fig. 1A , Fig. 2A Supplementary Fig. 3B, Fig. 1A ).
Median OS in patients with bone metastases was 18.5 mo (95% CI 10.2-NR) with nivolumab and 13.8 mo (95% CI 7.0-16.4) with everolimus ( Supplementary Fig. 4A,  Fig. 1A ). Median OS in patients with liver metastases was Supplementary Fig. 4B ; Fig. 1A ). Median OS in patients with lung metastases was 25.0 mo (95% CI 20.4-NR) with nivolumab and 18.7 mo (95% CI 16.2-21.2) with everolimus ( Supplementary Fig. S4C, Fig.  1A ).
OS by prior therapy
Median OS in patients with prior sunitinib or pazopanib or interleukin-2 therapy was longer with nivolumab than with everolimus or was not yet reached for nivolumab ( Fig. 3,  Fig. 1A ; reported previously for sunitinib and pazopanib in the nivolumab arm [14] ). Fig. 4,  Fig. 1A) .
When the overall treated population was divided according to[ 2 _ T D $ D I F F ] first-line therapy duration, median OS was longer for both treatment arms in patients with 6 mo compared [ 4 _ T D $ D I F F ] with <6 mo on first-line therapy and was longer with nivolumab compared [ 4 _ T D $ D I F F ] with everolimus (
Median OS in patients with one prior antiangiogenic therapy was 23.6 mo (95% CI 20.8-NR) with nivolumab and 19.9 mo (95% CI 17.7-24.7) with everolimus ( Fig. 1A) .
3.6.
Interaction test for each subgroup
An interaction test of treatment and each subgroup with OS revealed a significant interaction for MSKCC risk group (p = 0.0475). There was no evidence of an interaction for other subgroups.
ORR for each subgroup
ORR favored nivolumab over everolimus in all subgroups, most notably in patients with poor MSKCC risk, aged at least 65 yr, one site of metastasis, lung metastases, prior pazopanib therapy, and two prior antiangiogenic therapies (Fig. 1B) . There was no evidence of an interaction between treatment and each subgroup with ORR.
Safety for each subgroup
The incidence of grade 3 or 4 TRAEs was lower in the nivolumab arm compared [ 4 _ T D $ D I F F ] with the everolimus arm across subgroups ( Table 2 ). The incidence of grade 3 or 4 TRAEs in the nivolumab arm was half or less than half the incidence observed with everolimus in the following subgroups: favorable MSKCC risk (15% vs 40%); favorable IMDC risk (20% vs 41%); intermediate IMDC risk (17% vs 36%); at least 65 yr of age (16% vs 39%); one site of metastasis (15% vs 33%); lung metastases (17% vs 37%); prior interleukin-2 therapy (19% vs 38%); at least 6 mo on first-line therapy (17% vs 37%); and two prior antiangiogenic therapies (17% vs 36%; Table 2 ). There was no evidence of an interaction between treatment and each subgroup with any TRAE.
Discussion
With a minimum follow-up of 14 mo in previously treated patients with aRCC, OS and ORR favored nivolumab over everolimus for multiple subgroups. Within the nivolumab arm, ORR for most subgroups was similar and consistent with the overall ORR reported previously [7] . Median OS was greater and mortality rate was lower with nivolumab than with everolimus in all MSKCC risk groups, with the largest difference in patients with poor risk. The small number of events and short duration of follow-up in the favorable risk group limited the ability to observe robust OS differences between arms. The large difference for poor-risk patients suggests that further investigation of the characteristics of these patients, such as tumor biology, is needed to better understand this finding. One explanation, yet to be formally analyzed, is the potential presence of a higher mutational load in poor-risk patients, a phenomenon that in some cases has been correlated with better efficacy of PD-1 inhibitors. This is possibly because of the higher levels of lymphocytes expressing immune inhibitory signals in the tumor microenvironment that can be targeted by PD-1 inhibitors [15, 16] . The improved OS with nivolumab versus everolimus in patients with liver or bone metastases, which are associated with high incidence and poor prognosis [3, 17, 18] , further demonstrates that patients with poor prognostic features benefit from treatment with nivolumab.
There are some suggestions that response to nivolumab may be influenced by prior effect of tyrosine kinase inhibitors on the tumor microenvironment or their potential immune effect [14, 19, 20] . Although this study did not directly address the tumor microenvironment or the sequence of therapy, we did observe that OS was improved with nivolumab for all three prior therapies evaluated (sunitinib, pazopanib, and interleukin-2). Interleukin-2 is currently indicated in first-line treatment for a select group of patients with excellent performance status and normal organ function [21] . The small number of patients with prior interleukin-2 treatment enrolled and clinical selection criteria that impact decisions to treat with interleukin-2 preclude substantial clinical inferences. However, the favorable hazard ratio for nivolumab versus everolimus may imply a special impact of immune system manipulation by immunotherapies such as interleukin-2 that may result in benefit from subsequent treatment with an immune checkpoint inhibitor.
the superior OS for nivolumab was maintained regardless of the duration of first-line therapy, suggesting that a switch from a tyrosine kinase inhibitor to nivolumab, either for a lack of response or toxicity (subgroup with <6 mo of first-line therapy) or following potentially successful firstline therapy (subgroup with 6 mo of first-line therapy) provides a survival benefit.
The incidence of all-grade and grade 3 or 4 TRAEs in each subgroup was lower with nivolumab than with[ 5 _ T D $ D I F F ] everolimus and was similar to TRAEs noted in the overall population [7] . Notably, both younger and older patients had a similar incidence of grade 3 or 4 TRAEs. This observation, coupled with the improved OS with nivolumab versus everolimus in younger and older patients, suggests that older age did not preclude clinical benefit. Some limitations should be noted, including the post hoc nature of the analyses and the differing sample sizes within subgroups. The small sample size in some subgroups limits the interpretation of those results and may have contributed to the large range for some 95% CIs associated with hazard ratios for death and difference in ORR. Analyses with more patients are needed to validate those results. Furthermore, in the subgroup analyses of individual sites of metastases, some patients with multiple sites of metastases were represented in more than one subgroup, which complicates interpretation of OS by number of sites of metastases.
The broad benefit of nivolumab versus everolimus in terms of OS and ORR with respect to patient demographics, clinical characteristics, and prior therapies may provide additional insight that will allow clinicians to make informed decisions. With the increasing number of therapies available to treat aRCC, predicting outcomes, possibly through the development of nomograms based on baseline disease characteristics and prior therapies, will help to increase the individualized approach to treatment in an effort to improve survival [22] . Further research should focus on the development of predictive models of outcomes more aligned with immunotherapy in accordance with findings from this study.
In conclusion, consistent with the benefit demonstrated in the overall population from CheckMate 025 [7] , a trend for OS and ORR benefit with nivolumab versus everolimus was observed for multiple subgroups, including prognostic risk categories, age, number and sites of metastases, and prior therapies, without specific safety concerns. Efficacy with nivolumab is notable in patients with poor risk features, including those in the poor MSKCC risk group, those with bone metastases, and those with more than one site of metastasis. These results further support the use of nivolumab as a new standard of care [21, 23, 24] for a broad range of patients with previously treated aRCC.
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